Next thing we know MTXX will be using these drs, lol. have we seen them anywhere else?
The Quigley Corporation's New Formulation Found to
Reduce Influenza Impact in New Study
2003-01-14 07:32 (New York)
Quigley Pharma Nasal Formula Effective in UK Test Conducted by Retroscreen
Virology Ltd.
DOYLESTOWN, Pa., Jan. 14 /PRNewswire-FirstCall/ --
The Quigley Corporation (Nasdaq: QGLY) today announced that a Patent
Application previously assigned to The Quigley Corporation for an all-natural
compound was found effective in reducing the impact of influenza. Quigley
Pharma Inc., the Company's wholly owned ethical pharmaceutical subsidiary,
developed the formula.
The study was designed to test the efficacy of the Quigley Pharma formula
in a more advanced influenza model.
Retroscreen Virology Ltd., the research virology company affiliated with
the University of London, conducted the study. Professor John S. Oxford, the
firm's senior scientist, is Professor of Virology at St. Bartholomew's and The
Royal London School of Medicine and Dentistry at the University of London. He
is the co-author of two standard texts on Influenza and Virology and has
published 250 scientific papers throughout the world.
The study report concluded that, "The data indicated that intranasal
administration of the (Quigley Pharma) nasal spray was effective in this
model, with slightly differing symptom resolutions."
In a previous statement, Professor Oxford said that an independent audit
of his previously conducted in-vitro study of the new Quigley Pharma
formulation had been confirmed to be effective in killing three virulent
strains of current Influenza `A' and `B' viruses. At that time he recommended
that additional model studies be undertaken, which, if successful, he would
publish in a reputable medical journal.
These additional studies have now been successfully completed, and
according to Professor Oxford, are encouraging. Professor Oxford said, "It is
now important that further investigations are considered to determine whether
lower concentrations of the test compounds will be as effective and that there
is a dose response. When we have sufficient data regarding toxicity, a human
study might be considered. That study would consist of human influenza
challenge testing."
Guy J. Quigley, President, Chairman and Chief Executive Officer of The
Quigley Corporation, stated: "At the conclusion of the dosage response and
toxicity testing, we will consider the most appropriate strategy for the
Company to pursue in this process. We are continuing our ongoing research and
development efforts at Quigley Pharma. Under the direction of Dr. Richard
Rosenbloom, we hope to continue developing an exciting pipeline of potential
new all-natural medications to bring to the market."
Dr. Rosenbloom stated: "We are greatly encouraged by the clinical and pre-
clinical studies conducted on Quigley Pharma formulations to date and the
continuing progress toward the approval process."
Influenza can cause localized epidemics and global pandemics of acute
respiratory infections. Although influenza is mostly associated with a benign
and self-limiting condition, there is a significant link between mortality and
infection of children, elderly, and the persons with impaired immunity
systems.
About The Quigley Corporation
The Quigley Corporation (Nasdaq: QGLY) is a leading developer and marketer
of diversified health products including the Cold-Eeze(R) family of patented
zinc gluconate glycine (ZIGG(TM)) lozenges, gums and sugar-free tablets.
Cold-Eeze is the only (ZIGG(TM)) lozenge proven in two double-blind studies to
reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In
addition to Over-The-Counter (OTC) products, the Company has formed Quigley
Pharma Inc. (www.QuigleyPharma.com), a wholly owned ethical pharmaceutical
subsidiary, to introduce a line of patented prescription drugs. The Quigley
Corporation's customers include leading national wholesalers and distributors,
as well as independent and chain food, drug and mass merchandise stores and
pharmacies.
No claims are being made for the potential medicine discussed in this
press release to be safe, effective, or approved by the Federal Food and Drug
Administration (FDA).
Certain statements in this press release are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995 and
involve known and unknown risk, uncertainties and other factors that may cause
the Company's actual results, performance or achievements to be materially
different from the results, performance or achievements expressed or implied
by the forward-looking statement. Factors that impact such forward-looking
statements include, among others, changes in worldwide general economic
conditions, changes in interest rates, government regulations, and worldwide
competition.
SOURCE The Quigley Corporation
-0- 01/14/2003
/CONTACT: Media: Donald W. Schuster of The Torrenzano Group,
+1-212-681-1700 ext. 103, for Quigley Corporation; or Investors: The Quigley
Corporation Shareholder Relations, +1-267-880-1111/
/Web site: quigleypharma.com /
/Web site: quigleyco.com /
(QGLY)
CO: Quigley Corporation; Quigley Pharma Inc.; Retroscreen Virology Ltd.
ST: Pennsylvania, England
IN: MTC HEA
SU: SVY
-0- Jan/14/2003 12:32 GMT |
